Changing lives through cell survival
Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide keeps more cells alive longer. It utilizes the same properties that help animals survive in arctic temperatures, and it has the capability to change regenerative medicine forever.
With AAGP®, health therapies will become more effective, more affordable and more accessible. We will get closer to cures for conditions such as Type 1 diabetes, macular degeneration, heart disease and stroke. More lives will improve, and more people will get the treatments they deserve.
Public listing on open market
Initiation of pre-clinical type 1 diabetes research at the University of Alberta (Dr. James Shapiro)
Lead Scientist, Dr. Geraldine Deliencourt awarded prestigious Francinov medal for scientific excellence in the field of chemistry forming the basis of AAGP®
Good Manufacturing Practice processing established and preliminary toxicology assessment successful (with AmbioPharm)
Patent filing for type 1 diabetes with islet transplantation
Clarence Smith installed as Chief Executive Officer
Macular degeneration cell therapy program started at the University of British Columbia
Patent filing for macular degeneration with induced pluripotent stem cells
Preclinical validation of AAGP® in type 1 diabetes and peer-reviewed paper
Patent expanded for macular degeneration with induced pluripotent stem cells
Patent filing for macular degeneration with neurosensory precursor cells
Pre-clinical proof of concept for AAGP® in macular degeneration and peer-reviewed paper
Acquired approval from Health Canada for Phase-1a clinical trial type 1 diabetes using islet cell grafting (Dr. James Shapiro)
Enhanced biological production and hematopoietic stem cell recovery research program initiated at the University of British Columbia
Cardiovascular research program started at Dalhousie University (Dr. Thomas Pulinilkunnil)
Completed pre-clinical macular degeneration cell graft studies (Dr. Gregory Evans)
Completed pre-clinical ocular safety study in small animal (EyeCro)
Completed pre-clinical ocular safety study in large animal (Charles River)
Completed pre-clinical ocular efficacy study (EyeCro)
Acquired approval from Health Canada for Phase-1b clinical trial type 1 diabetes using islet cell grafting
Established partnership with IQVIA to execute go-forward strategy for dry eye disease clinical trial and commercialization program
Patent filing for AAGP® for use in dry eye disease
Pre-clinical validation of AAGP® in macular degeneration in peer-reviewed paper
Completion of eye drop formulation for validation studies
We are moving cell survival forward by addressing the health conditions that affect our lives. See where we are today and where we are heading next.
The leaders at ProtoKinetix have a clear vision for the future of the company and for the future of regenerative medicine. Learn more about their backgrounds.